-
Friday, 02/02/2024
Ana Motos Awarded the Prestigious RESPIRE - MSCA Fellowship
Dr. Ana Motos, a promising researcher trained in our group in the field of respiratory infections, has been awarded the prestigious RESPIRE - Marie Skłodowska-Curie Actions (MSCA) fellowship. This esteemed grant, funded by the European Respiratory Society and the European Commission, is designed to support groundbreaking research and innovation. Known for its highly competitive selection process, the RESPIRE - MSCA grant provides not only financial support but also access to a vast network of research and training opportunities across Europe.
With the MSCA grant, Dr. Motos will embark on a two-year research journey at the University of Nantes under the supervision of Prof. Antoine Roquilly. Dr. Motos' project, titled "Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures," aims to define sub-phenotypes of respiratory microbiomes associated with the emergence of resistance during treatment and treatment failure. The project's implications extend beyond the scientific community, as findings may contribute to the development of targeted therapeutic approaches for pneumonia, improving patient outcomes, and addressing antibiotic resistance challenges.
-
Thursday, 02/01/2024
Kasra Kiarostami publishes Debut Paper as Lead Author
kasra Kiarostami wants to thanks to Prof. Antoni Torres, Dr. Laia Fernandez, Dr. Ana Motos and all collaborators in the Theravance project the recent article " The efficacy of telavancin in comparison with linezolid on endotracheal tube biofilm in pigs with methicillin-resistant Staphylococcus aureus pneumonia" was published in International Journal of Antimicrobial Agents journal. The first author is kasra Kiarostami.
In summary, this research compared the efficacy of telavancin and linezolid in addressing biofilms on endotracheal tubes (ETT) in a porcine model simulating methicillin-resistant Staphylococcus aureus (MRSA) ventilator-associated pneumonia (VAP). While MRSA loads on the ETT and cuff did not significantly differ among control, linezolid, and telavancin groups, a notable finding revealed telavancin's ability to reduce MRSA biofilm on the ETT. This suggests potential advantages for telavancin in clinical settings, especially for elective patients. Despite acknowledging the study's limitation of a small sample size, we argue that this model aligns with real-world VAP scenarios in critically ill patients, emphasizing the need for further investigation. The study highlights telavancin's potential significance in combating biofilms and improving treatment approaches for VAP."
Thank you!
-
Thursday, 02/01/2024
New Study Coordinator of the Animal Model
We are delighted to announce that Dr. Flavia Galli has been appointed as the new Research Study Coordinator for our animal model program. With a background in anesthesiology and critical care medicine, Dr. Galli received her medical training at Policlinico Universitario A. Gemelli of Rome, bringing a wealth of expertise to our team.
Over the past two years, Dr. Galli has contributed significantly to our organization as a clinical research fellow, dedicating her efforts to researching the animal model and spearheading projects related to critically ill patients and COVID-19. Her commitment to advancing medical knowledge and improving patient outcomes has been exemplary.
In her new role, Dr. Galli will assume responsibility for the design, implementation, and coordination of animal protocols, ensuring the highest standards of scientific rigor. Additionally, she will oversee the analysis of data and scientific production, driving forward innovative research initiatives.
Furthermore, Dr. Galli will play a pivotal role in facilitating collaboration with incoming international fellows, fostering an environment of knowledge exchange and collaboration.
Congratulations Flavia!
-
Friday, 01/19/2024
New Fellow from Italy
Davide Calabretta, MD
Resident in Anesthesiology and Intensive Care Medicine at the University of Milan.
Staying in IDIBAPS from May 2023 to April 2024.
During his period as a fellow he has been involved in the study of hospital-acquired pneumonia and ventilator-associated pneumonia, investigating the clinical impact of the recommendations of 2017 ERS/ESICM/ESCMID/ALAT guidelines on outcomes and studying new nonpharmacological treatment approaches in the animal model.
-
Friday, 01/19/2024
New Fellow from Italy
Federica Viola Piedepalumbo, MD, pneumology resident at respiratory unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Staying in IDIBAPS from November 2023 to April 2024.
Her research interests are bronchiectasis, mycobacterial diseases, and respiratory infections.
During her period as a fellow, she has been involved in the study of new nonpharmacological treatment approaches in the animal model and in the study of safety of steroids in severe community-acquired pneumonia (CAP).
-
Wednesday, 01/10/2024
SEPAR AWARDS 2023 Leticia Bueno
-
Friday, 12/15/2023
Dr Miquel Ferrer Awarded Grant for Pioneering Precision Medicine Project
Dr. Miquel Ferrer has been honored with the esteemed Knowledge Generation Projects grant for his groundbreaking research project, "Interaction between risk factors, complications, sequelae, and biological basis in acute respiratory failure: towards precision medicine" (PIRAMYD). This innovative initiative, aimed at revolutionizing the treatment and management of acute respiratory failure through personalized medicine, has received recognition from the Spanish Agency of Research for its rigor and potential impact.
The PIRAMYD project, developed in collaboration with Dr. José Ángel Lorente and the team at Getafe University Hospital, focuses on deciphering the intricate relationships between genetic and environmental risk factors and their effects on patients' outcomes following acute respiratory failure. Through advanced omics data analysis, the project endeavours to pinpoint biomarkers that will facilitate tailored medical interventions for each patient, marking a significant advancement in personalized healthcare.
This grant not only provides vital financial support for the ambitious research but also underscores the significance and ingenuity of the PIRAMYD project within the medical community. Dr. Ferrer's dedication to advancing precision medicine promises to yield transformative outcomes for patient care and underscores Spain's leadership in cutting-edge medical research.
-
Friday, 10/20/2023
Denise Battaglini read her doctoral thesis
Denise Battaglini read her doctoral thesis
Denise Battaglini, an italian fellow, read her doctoral thesis on October, 20th , 2023 at the Faculty of Medicine of the University of Barcelona. Her thesis entitled: Epidemiology, risk factors and new therapeutic strategies for ventilatorassociated pneumonia: preclinical and clinical perspectives has obtained the Cum Laude qualification.
Congratulations Denise!
-
Friday, 06/30/2023
ISICIP 2023 E-POSTERS SUBMISSIONS
27th International Symposium on Infections in the Critically ill patient to be held on October 5-6 in Barcelona. ISICIP 2023
The deadline to submit your e-Poster is September 15th,2023
-
Friday, 04/28/2023
The viral load of COVID-19 at admission to the ICU determines the prognosis of patients
Madrid, April 26, 2023. New research reveals the importance of 'viral storm' in critical patients with COVID-19. The work is published in the journal The Lancet Microbe and has been carried out by several groups in the area of Respiratory Diseases (CIBERES) and the area of Infectious Diseases (CIBERINFEC) of the Biomedical Research Center in Network (CIBER)consortium attached to the Carlos III Health Institute (ISCIII). The results show that viral load in blood at admission to the ICU is a determining factor in the prognosis of critical patients with COVID-19.